Lilly's Next-Gen Obesity Shot Shows Best-In-Class Weight Loss In Study Shares of Eli Lilly are higher in premarket trading after the company unveiled blowout topline results for its next-generation obesity drug retatrutide, which delivered more than 23% weight loss over 68 weeks - the strongest perf......